Alcresta Raises $10M Series A

Alcresta, a Newton, Mass.-based company that is developing enzyme-based nutritional products, has raised $10 million in Series A financing led by Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. PRESS RELEASE: Alcresta, a company developing innovative enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, today announced a $10 million Series […]

Sanofi Invests $125 Million in Warp Drive Bio

Boston-based Third Rock Ventures today launched the genomic search engine start-up, Warp Drive Bio, as part of a partnership with the French pharmaceutical company Sanofi. Sanofi is investing $125 million into the company, which Third Rock — an venture firm as well as incubator — has been developing for the last two years. PRESS RELEASE: […]

VC-backed Seventh Sense Inks $3.28M Grant

Seventh Sense Biosystems Inc., a Cambridge, Mass.-based developer of technology for decentralized diagnostic testing, has sealed a $3.28 million grant from the Bill & Melinda Gates Foundation. Formed in 2008, the company is backed by investors including Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.

Third Rock Ventures Launches Ember Therapeutics with $34M

Boston-based Third Rock Ventures has unveiled a new company, Ember Therapeutics, a product-focused company that’s trying to harness breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Third Rock, a venture firm that helps incubate life sciences companies, has given Ember $34 million in Series A financing. PRESS RELEASE: BOSTON, Dec […]

Agios Pharmaceuticals Seals $78M Series C

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Allena Pharmaceuticals Launches with $15M

Allena Pharmaceuticals Inc., a company developing oral protein therapeutics, has raised $15 million in a first round of venture funding. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the Series A round. The funding will help fund development. Allena Pharmaceuticals is based in Newton, Mass.

Third Rock Ventures Launches SAGE Therapeutics

Third Rock Ventures has launched SAGE Therapeutics with a $35 million Series A financing. SAGE’s efforts focus on advancing a pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI).

TOPICA Pharmaceuticals Closes $27M Series B

Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corp. have poured $27 million into privately held biotechnology company TOPICA Pharmaceuticals. The Series B round will be used for continued development of the company’s broad-spectrum topical antifungal agent, the company said Tuesday.

Foundation Medicine Closes A Round with $33.5M

Foundation Medicine Inc., a Cambridge, Mass.-based cancer diagnostics company, has added to its Series A financing, closing the round with $33.5 million. New investors Kleiner Perkins Caufield & Byers and Google Ventures join Third Rock Ventures in the round. Brook Byers, a partner with Kleiner Perkins, and Google Ventures’ Krishna Yeshwant will join Foundation Medicine’s board.

Zafgen Inks $33M Series C for Obesity Drug

Cambridge, Mass.-based pharmaceutical company Zafgen Inc., which is developing novel obesity therapeutics, has closed on $33 million in Series C financing. Existing shareholders are leading the round, including Atlas Venture and Third Rock Ventures. The money will help support development of Zafgen’s pipeline and to advance its lead treatment for severe obesity into Phase 2 clinical studies.

Lotus Tissue Repair Closes $26M Series A

Lotus Tissue Repair Inc. has raised $26 million in a Series A round led by Third Rock Ventures. The company is developing technology to be used in the treatment of dystrophic epidermolysis bullosa, “an orphan disease that causes devastating skin blisters, morbidity and early mortality,” the company said in a release. The infusion of cash will be used to continue development.

Constellation Pharmaceuticals Closes on $15M

Constellation Pharmaceuticals has raised $15 million in an extension to its Series B round, the company announced Monday. Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures – all existing shareholders – participated in the round. The latest infusion will help Constellation move its products toward clinical development. The company develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders and other diseases.

Seventh Sense Biosystems Adds $4.5M

Cambridge, Mass.-based Seventh Sense Biosystems has raised $4.5 million of a planned $10 million Series A round, the company said Wednesday. Existing investors Flagship Ventures, Polaris Venture Partners and Third Rock Ventures provided the tranche, which will be used for continued development of the company’s blood sampling technology.

Bluebird Bio Closes $30M Venture Round

Cambridge, Mass.-based Bluebird Bio, which is developing gene therapies for genetic disorders, has inked $30 million in fresh capital from investors including ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group. ARCH Venture Partners was a new investor in the company, and the firm’s managing director Steven Gillis will join Bluebird Bio’s board. The company completed a $35 million Series B in early 2010.

TARIS Biomedical Inks $18.3M Series B

Lexington, Mass.-based TARIS Biomedical, which is developing therapies to treat bladder disease, has raised $18.3 million in Series B financing. New investors Third Rock Ventures led the round, which included participation from existing shareholders Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners. The company’s prior bridge financing was also converted into equity in connection with the financing round. Third Rock’s Cary Pfeffer will join the TARIS board.

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget